Bevacizumab玻璃体腔注射联合手术及激光治疗新生血管性青光眼临床观察  

Clinical observation on the treatment of neovascular glaucoma by intravitreal injection of bevacizumab combined with operation and laser

作　　者：潘敏敏[1] 李淑萍[1] 孟娜[1] 焦演歌[1] 杨晓峰[1] 

机构地区：[1]河南科技大学第二附属医院眼科,河南洛阳471000

出　　处：《中国当代医药》2011年第12期46-47,共2页China Modern Medicine

摘　　要：目的:观察玻璃体腔注射Bevacizumab联合小梁切除术及视网膜光凝术治疗新生血管青光眼临床疗效。方法:18例18眼药物及手术不能控制的新生血管青光眼患者行玻璃体腔注射Bevacizumab 0.1 ml/2.5 mg,新生血管消退后行小梁切除术及视网膜光凝术。结果:平均随访6个月,眼压控制完全成功13眼,部分成功4眼,眼压未控制1眼。11眼视力稳定,6眼稍有提高(1眼失访)。结论:玻璃体腔注射Bevacizumab对新生血管青光眼的治疗有降低眼压及辅助手术的积极作用。objective： To observe the clinical effect of the treatment of neovascular glaucoma by Intravitreal injection of bevacizumab combined with operation and laser.Methods： Intravitreal injection of bevacizumab（0.1 ml/2.5 mg） in 18 eyes of 18 neovascular glaucomas beyond the control of drugs and surgery.Trabeculectomy and retinal photocoagulation were performed after the neovascularization dissipated.The patients were followed up 6 months on average.Results： Intraocular pressure was complete controlled successfully in 13 eyes,partly controlled in 4 eyes,failed to control in 1 eye.The vision of 11 eyes was stable,6 eyes was slightly improved,while 1 eye was lost to follow.Conclusion： Intravitreal injection of bevacizumab could reduce intraocular pressure and assist operation which had a positive effect on the treatment of neovascular glaucoma.

关 键 词：BEVACIZUMAB 玻璃体腔注射 新生血管青光眼 激光治疗 

分 类 号：R775[医药卫生—眼科]